Abstract
Background Liver cancer is one of the cancers that consistently ranks among the top five cancers in terms of incidence and mortality in many countries. Ultrasound is widely used in liver tumor screening or preliminary diagnosis. Enhanced CT is widely used in liver tumor diagnosis. However, false-positive results of ultrasound and enhanced CT will bring unnecessary mental pain, expensive examination costs, physical injuries, and even organ resection and loss of function; while false-negative results of enhanced CT will bring delayed treatment, and the patients will thus have to bear the adverse consequences of poor prognosis, high treatment costs, poor quality of life, and short survival period. There is an urgent need to find convenient, cost-effective and non-invasive diagnostic methods to reduce the false-positive rate of ultrasound and the false-negative and false-positive rates of enhanced CT for liver tumors. The purpose of this study is to evaluate the diagnostic value of YiDiXie™-HS, YiDiXie™-SS and YiDiXie™-D in liver tumors.
Patients and methods This study finally included 166 subjects (the malignant group, n=134; the benign group, n=32). Remaining serum samples from the subjects were collected and tested using the YiDiXie™ all-cancer detection kit, which was applied to assess the sensitivity and specificity of YiDiXie™-SS, YiDiXie™-HS and YiDiXie™-D, respectively.
Results YiDiXie™-SS had a sensitivity of 98.5% (95% CI: 94.7% - 99.7%; 132/134) in patients with a positive hepatic ultrasound, a specificity of 65.6% (95% CI: 48.3% - 79.6%; 21/32). Compared with enhanced CT alone, sequential use of YiDiXie™-SS and CT had comparable sensitivity, while the false-positive rate decreased from 37.5% (95% CI: 22.9% - 54.7%; 12/32) to 12.5% (95% CI: 5.0% - 28.1%; 4/32). This means that the application of YiDiXie™-SS reduced the false-positive rate of ultrasound by 65.6% (95% CI: 48.3% - 79.6%; 21/32) and the false-positive rate of enhanced CT by 66.7% with essentially no increase in the number of malignant tumors missed. YiDiXie™-HS had a sensitivity of 90.9% (95% CI:78.8% - 96.4%; 40/44) in patients with negative enhancement CT, a specificity of 85.0% (95% CI: 64.0% - 94.8%; 17/20). This means that YiDiXie™-HS reduced the false-negative rate of enhanced CT by 90.9% (95% CI: 78.8% - 96.4%; 40/44). YiDiXie™-D had a sensitivity of 31.1% (95% CI: 22.5% - 41.3%; 28/90) in patients with a positive enhanced CT; specificity was 91.7% (95% CI: 64.6% - 99.6%; 11/12). This means that YiDiXie™-D reduces the false positive rate of enhanced CT by 91.7% (95% CI: 64.6% - 99.6%; 11/12).
Conclusion YiDiXie™-SS has a significant effect on reducing the false-positive rate of ultrasound and enhanced CT for liver tumors, with no significant delay in malignancy treatment. YiDiXie™-HS substantially reduces the false negative rate of enhanced CT. YiDiXie™-D substantially reduces the false positive rate of enhanced CT. The YiDiXie™ test has significant diagnostic value in liver tumors, and is expected to solve the problems of “high false-positive rate of ultrasound”, “high false-negative rate of enhanced CT” and “high false-positive rate of enhanced CT” in liver tumors.
Clinical trial number ChiCTR2200066840.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
ChiCTR2200066840
Funding Statement
This work was supported by Shenzhen High-level Hospital Construction Fund, Clinical Research Project of Peking University Shenzhen Hospital (LCYJ2020002, LCYJ2020015, LCYJ2020020, LCYJ2017001).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee of Peking University Shenzhen Hospital gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are contained in the manuscript.
